These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

654 related articles for article (PubMed ID: 23279603)

  • 21. Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome.
    Morin-Papunen L; Rautio K; Ruokonen A; Hedberg P; Puukka M; Tapanainen JS
    J Clin Endocrinol Metab; 2003 Oct; 88(10):4649-54. PubMed ID: 14557435
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma cytokines in obese women with polycystic ovary syndrome, before and after metformin treatment.
    Jakubowska J; Bohdanowicz-Pawlak A; Milewicz A; Szymczak J; Bednarek-Tupikowska G; Demissie M
    Gynecol Endocrinol; 2008 Jul; 24(7):378-84. PubMed ID: 18645710
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasma adiponectin levels in women with polycystic ovary syndrome: impact of metformin treatment in a case-control study.
    Singh S; Akhtar N; Ahmad J
    Diabetes Metab Syndr; 2012; 6(4):207-11. PubMed ID: 23199540
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum resistin and adiponectin levels in young non-obese women with polycystic ovary syndrome.
    Arikan S; Bahceci M; Tuzcu A; Kale E; Gökalp D
    Gynecol Endocrinol; 2010 Mar; 26(3):161-6. PubMed ID: 20148738
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of metformin on serum visfatin levels in patients with polycystic ovary syndrome.
    Ozkaya M; Cakal E; Ustun Y; Engin-Ustun Y
    Fertil Steril; 2010 Feb; 93(3):880-4. PubMed ID: 19111298
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy.
    Diamanti-Kandarakis E; Spina G; Kouli C; Migdalis I
    J Clin Endocrinol Metab; 2001 Oct; 86(10):4666-73. PubMed ID: 11600523
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diet, physical exercise and Orlistat administration increase serum anti-Müllerian hormone (AMH) levels in women with polycystic ovary syndrome (PCOS).
    Vosnakis C; Georgopoulos NA; Rousso D; Mavromatidis G; Katsikis I; Roupas ND; Mamali I; Panidis D
    Gynecol Endocrinol; 2013 Mar; 29(3):242-5. PubMed ID: 23194076
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inflammatory-metabolic parameters in obese and nonobese normoandrogenemic polycystic ovary syndrome during metformin and oral contraceptive treatment.
    Kilic S; Yilmaz N; Zulfikaroglu E; Erdogan G; Aydin M; Batioglu S
    Gynecol Endocrinol; 2011 Sep; 27(9):622-9. PubMed ID: 21105835
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebo-controlled trial.
    Chou KH; von Eye Corleta H; Capp E; Spritzer PM
    Horm Metab Res; 2003 Feb; 35(2):86-91. PubMed ID: 12734787
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin.
    Diamanti-Kandarakis E; Paterakis T; Alexandraki K; Piperi C; Aessopos A; Katsikis I; Katsilambros N; Kreatsas G; Panidis D
    Hum Reprod; 2006 Jun; 21(6):1426-31. PubMed ID: 16497699
    [TBL] [Abstract][Full Text] [Related]  

  • 31. C-reactive protein levels are unaffected by metformin during pretreatment and an IVF cycle in women with polycystic ovary syndrome.
    Kjøtrød SB; Romundstad P; von Düring V; Sunde A; Carlsen SM
    Fertil Steril; 2008 Mar; 89(3):635-41. PubMed ID: 17548076
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive value of glucose-insulin ratio in PCOS and profile of women who will benefit from metformin therapy: obese, lean, hyper or normoinsulinemic?
    Onalan G; Goktolga U; Ceyhan T; Bagis T; Onalan R; Pabuçcu R
    Eur J Obstet Gynecol Reprod Biol; 2005 Dec; 123(2):204-11. PubMed ID: 16316811
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma ghrelin, obesity, and the polycystic ovary syndrome: correlation with insulin resistance and androgen levels.
    Pagotto U; Gambineri A; Vicennati V; Heiman ML; Tschöp M; Pasquali R
    J Clin Endocrinol Metab; 2002 Dec; 87(12):5625-9. PubMed ID: 12466363
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome.
    Ortega-González C; Luna S; Hernández L; Crespo G; Aguayo P; Arteaga-Troncoso G; Parra A
    J Clin Endocrinol Metab; 2005 Mar; 90(3):1360-5. PubMed ID: 15598674
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of metformin and pioglitazone treatment on cardiovascular risk profile in polycystic ovary syndrome.
    Ziaee A; Oveisi S; Abedini A; Hashemipour S; Karimzadeh T; Ghorbani A
    Acta Med Indones; 2012 Jan; 44(1):16-22. PubMed ID: 22451180
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metformin versus metformin plus rosiglitazone in women with polycystic ovary syndrome.
    Liao L; Tian YJ; Zhao JJ; Xin Y; Xing HY; Dong JJ
    Chin Med J (Engl); 2011 Mar; 124(5):714-8. PubMed ID: 21518564
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sustainability of 8% weight loss, reduction of insulin resistance, and amelioration of atherogenic-metabolic risk factors over 4 years by metformin-diet in women with polycystic ovary syndrome.
    Glueck CJ; Aregawi D; Agloria M; Winiarska M; Sieve L; Wang P
    Metabolism; 2006 Dec; 55(12):1582-9. PubMed ID: 17142128
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome.
    Gambineri A; Pelusi C; Genghini S; Morselli-Labate AM; Cacciari M; Pagotto U; Pasquali R
    Clin Endocrinol (Oxf); 2004 Feb; 60(2):241-9. PubMed ID: 14725687
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metformin therapy increases insulin-like growth factor binding protein-1 in hyperinsulinemic women with polycystic ovary syndrome.
    Pawelczyk L; Spaczynski RZ; Banaszewska B; Duleba AJ
    Eur J Obstet Gynecol Reprod Biol; 2004 Apr; 113(2):209-13. PubMed ID: 15063962
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study.
    Tang T; Glanville J; Hayden CJ; White D; Barth JH; Balen AH
    Hum Reprod; 2006 Jan; 21(1):80-9. PubMed ID: 16199429
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.